Roanoke Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $3.84M | Sell |
34,280
-291
| -0.8% | -$30K | 1.32% | 31 |
|
|
2024
Q4 | $3.19M | Buy |
34,571
+10
| +0% | +$900 | 1.03% | 38 |
|
|
2024
Q3 | $2.9M | Buy |
34,561
+462
| +1% | +$35.3K | 0.91% | 39 |
|
|
2024
Q2 | $2.34M | Sell |
34,099
-211
| -0.6% | -$14.1K | 0.77% | 40 |
|
|
2024
Q1 | $2.51M | Buy |
34,310
+12
| +0% | +$923 | 0.82% | 41 |
|
|
2023
Q4 | $2.78M | Buy |
34,298
+12
| +0% | +$934 | 1.03% | 38 |
|
|
2023
Q3 | $2.57M | Sell |
34,286
-24
| -0.1% | -$1.85K | 1.05% | 39 |
|
|
2023
Q2 | $2.64M | Buy |
34,310
+12
| +0% | +$957 | 1.05% | 39 |
|
|
2023
Q1 | $2.85M | Buy |
34,298
+11
| +0% | +$911 | 1.21% | 33 |
|
|
2022
Q4 | $2.94M | Buy |
34,287
+10
| +0% | +$792 | 1.34% | 30 |
|
|
2022
Q3 | $2.12M | Sell |
34,277
-537
| -2% | -$33.9K | 1.01% | 39 |
|
|
2022
Q2 | $2.15M | Sell |
34,814
-587
| -2% | -$36.3K | 0.97% | 38 |
|
|
2022
Q1 | $2.1M | Sell |
35,401
-187
| -0.5% | -$12K | 0.78% | 45 |
|
|
2021
Q4 | $2.58M | Buy |
35,588
+11
| +0% | +$758 | 0.86% | 39 |
|
|
2021
Q3 | $2.48M | Buy |
35,577
+1
| +0% | +$70 | 0.88% | 39 |
|
|
2021
Q2 | $2.45M | Buy |
35,576
+3,612
| +11% | +$241K | 0.85% | 38 |
|
|
2021
Q1 | $2.07M | Sell |
31,964
-5,192
| -14% | -$335K | 0.9% | 37 |
|
|
2020
Q4 | $2.17M | Buy |
37,156
+183
| +0.5% | +$11K | 1.02% | 35 |
|
|
2020
Q3 | $2.34M | Sell |
36,973
-389
| -1% | -$27K | 1.27% | 25 |
|
|
2020
Q2 | $2.88M | Sell |
37,362
-2,651
| -7% | -$203K | 1.66% | 20 |
|
|
2020
Q1 | $2.99M | Buy |
40,013
+375
| +0.9% | +$25.9K | 2.01% | 14 |
|
|
2019
Q4 | $2.58M | Sell |
39,638
-7,885
| -17% | -$513K | 1.29% | 31 |
|
|
2019
Q3 | $3.01M | Sell |
47,523
-370
| -0.8% | -$24.2K | 1.41% | 23 |
|
|
2019
Q2 | $3.24M | Buy |
47,893
+194
| +0.4% | +$12.8K | 1.46% | 22 |
|
|
2019
Q1 | $3.1M | Sell |
47,699
-40
| -0.1% | -$2.66K | 1.44% | 21 |
|
|
2018
Q4 | $2.99M | Sell |
47,739
-141
| -0.3% | -$9.86K | 1.58% | 19 |
|
|
2018
Q3 | $3.7M | Sell |
47,880
-148
| -0.3% | -$11.2K | 1.66% | 17 |
|
|
2018
Q2 | $3.4M | Sell |
48,028
-450
| -0.9% | -$31.8K | 1.64% | 17 |
|
|
2018
Q1 | $3.65M | Buy |
48,478
+1,800
| +4% | +$143K | 1.76% | 16 |
|
|
2017
Q4 | $3.34M | Sell |
46,678
-2,238
| -5% | -$170K | 1.6% | 19 |
|
|
2017
Q3 | $3.96M | Sell |
48,916
-3,164
| -6% | -$242K | 1.87% | 16 |
|
|
2017
Q2 | $3.69M | Sell |
52,080
-2,028
| -4% | -$135K | 1.75% | 18 |
|
|
2017
Q1 | $3.67M | Sell |
54,108
-6,215
| -10% | -$437K | 1.75% | 18 |
|
|
2016
Q4 | $4.32M | Sell |
60,323
-1,349
| -2% | -$100K | 1.96% | 17 |
|
|
2016
Q3 | $4.88M | Sell |
61,672
-2,184
| -3% | -$177K | 2.2% | 12 |
|
|
2016
Q2 | $5.33M | Buy |
63,856
+1,669
| +3% | +$148K | 2.47% | 9 |
|
|
2016
Q1 | $5.71M | Sell |
62,187
-8,456
| -12% | -$763K | 2.65% | 7 |
|
|
2015
Q4 | $7.15M | Sell |
70,643
-6,700
| -9% | -$697K | 3.06% | 5 |
|
|
2015
Q3 | $7.59M | Sell |
77,343
-320
| -0.4% | -$35.5K | 2.79% | 4 |
|
|
2015
Q2 | $9.09M | Buy |
77,663
+534
| +0.7% | +$58.4K | 2.93% | 5 |
|
|
2015
Q1 | $7.57M | Sell |
77,129
-1,882
| -2% | -$191K | 2.48% | 11 |
|
|
2014
Q4 | $7.45M | Buy |
79,011
+2,815
| +4% | +$291K | 2.55% | 8 |
|
|
2014
Q3 | $8.11M | Sell |
76,196
-7,025
| -8% | -$688K | 3.33% | 2 |
|
|
2014
Q2 | $6.9M | Buy |
83,221
+3,121
| +4% | +$243K | 2.65% | 7 |
|
|
2014
Q1 | $5.68M | Buy |
80,100
+1,615
| +2% | +$127K | 2.5% | 8 |
|
|
2013
Q4 | $5.89M | Hold |
78,485
| – | – | 2.71% | 5 |
|
|
2013
Q3 | $5.38M | Buy |
+78,485
| New | +$4.69M | 2.61% | 8 |
|
Other funds holding GILD
Roanoke Asset Management's GILD Position: Q1 2025 in Review
Roanoke Asset Management reduced its Gilead Sciences (GILD) stake by 0.84% in Q1 2025, selling an estimated $30K and leaving 34,280 shares worth $3.84M. The position accounts for 1.32% of the portfolio, ranked #31.
Roanoke Asset Management first reported a position in GILD in Q3 2013 and has held it in 47 quarters since. The position peaked at $9.09M in Q2 2015. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.
- Roanoke Asset Management held 34,280 shares of Gilead Sciences worth $3.84M as of Q1 2025.
- Roanoke Asset Management sold 291 Gilead Sciences shares in Q1 2025, an estimated $30K.
- Gilead Sciences made up 1.32% of Roanoke Asset Management's portfolio in Q1 2025, its #31 holding.
- Roanoke Asset Management first reported a position in Gilead Sciences in Q3 2013 and has held it in 47 quarters since.
- Roanoke Asset Management's Gilead Sciences position peaked at $9.09M in Q2 2015.
- 2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.
Based on Roanoke Asset Management's 13F filing for Q1 2025, filed 13 May 2025.